托法替布治疗中重度类风湿关节炎的效果与安全性评价

Efficacy and safety evaluation of tofatib in the treatment of moderate to severe rheumatoid arthritis

目的探讨托法替布治疗中重度类风湿关节炎的效果与安全性。方法选取2019年10月至2020年10月本院收治的114例中重度类风湿关节炎患者作为研究对象,按照随机数字表法分为对照组和研究组,每组57例。对照组给予甲氨蝶呤治疗,研究组给予托法替布治疗,比较两组28个关节疾病活动性(DAS28)评分、视觉模拟评分法(VAS)评分、化验指标[C反应蛋白(CRP)、红细胞沉降率(ESR)、类风湿因子(RF)、肿瘤坏死因子-α(TNF-α)]、临床疗效、不良反应发生情况。结果治疗前,两组DAS28评分及VAS评分比较差异无统计学意义;治疗后,两组DAS28评分及VAS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组CRP、ESR、RF及TNF-α水平比较差异无统计学意义;治疗后,两组CRP、ESR、RF及TNF-α水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组治疗总有效率(94.7%)高于对照组(78.9%),差异有统计学意义(P<0.05)。研究组不良反应发生率(1.8%)低于对照组(14.0%),差异有统计学意义(P<0.05)。结论托法替布治疗中重度类风湿关节炎效果确切,不良反应少,不仅可有效缓解患者疼痛,减轻疾病活动性,还可消除炎症因子,具有较高的安全性,值得临床推广应用。

Objective To investigate the efficacy and safety of tofatib in the treatment of moderate to severe rheumatoid arthritis.Methods 114 patients with moderate to severe rheumatoid arthritis admitted to our hospital from October 2019 to October 2020 were selected as the research subjects,and they were divided into control group and study group according to the random number table method,with 57 cases in each group.The control group was treated with methotrexate,and the study group was treated with tofactib,the disease activity score 28 joint(DAS 28)score,visual analogue scale(VAS)score,laboratory indicators(C-reactive protein[CRP],erythrocyte sedimentation rate[ESR],rheumatoid factor[RF],tumor necrosis factor-α[TNF-α]),clinical efficacy and adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference in DAS 28 score and VAS score between the two groups;after treatment,the DAS 28 score and VAS score of the two groups were lower than those before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in CRP,ESR,RF and TNF-αlevels between the two groups;after treatment,the levels of CRP,ESR,RF and TNF-αof the two groups were lower than those before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).The total effective rate of treatment in the study group(94.7%)was higher than that in the control group(78.9%),and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group(1.8%)was lower than that in the control group(14.0%),and the difference was statistically significant(P<0.05).Conclusion Tofatib treatment of severe rheumatoid arthritis exact effect,less adverse reactions,not only can effectively relieve pain,reduce disease activity,but also eliminate inflammatory factors,with high safety,which is worthy of clinical promotion application.